Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108450
Filing Date
2025-08-14
Accepted
2025-08-14 08:10:54
Documents
78
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20250630.htm   iXBRL 10-Q 3099551
2 EX-31.1 cadl-ex31_1.htm EX-31.1 16810
3 EX-31.2 cadl-ex31_2.htm EX-31.2 16814
4 EX-32.1 cadl-ex32_1.htm EX-32.1 9841
5 EX-32.2 cadl-ex32_2.htm EX-32.2 10266
  Complete submission text file 0000950170-25-108450.txt   10093284

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20250630.xsd EX-101.SCH 1154287
81 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20250630_htm.xml XML 1651820
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 251214495
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)